

FORM 5A

ANNUAL LISTING SUMMARY

Introduction

The requirement to file this Form 5A does not apply to NV Issuers. NV Issuers must file a Form 51-102F2 Annual Information Form.

This Annual Listing Summary must be posted on or before the day on which the Issuer's annual financial statements are to be filed under the Securities Act. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies.

General Instructions

- (a) Prepare this Annual Listing Summary using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Listed Issuer Name: *BetterLife Pharma Inc.*

Website: www.abetterlifepharma.com

Listing Statement Date: *May 29, 2026*

Description(s) of listed securities(symbol/type): *BETR.CN*

Brief Description of the Issuer's Business: *Biotechnology company primarily focused on developing compounds for the treatment of mental disorders.*

Description of additional (unlisted) securities outstanding: *Warrants, stock options and performance stock units*

Jurisdiction of Incorporation: *British Columbia*

Fiscal Year End: <i>January 31, 2026</i>		
Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled): <i>Last Shareholders' Meeting – July 23, 2025</i>		
Financial Information as at: <i>January 31, 2026</i>		
	Current	Previous
Cash	\$12,570	\$8,180
Current Assets	\$219,903	\$224,963
Non-current Assets	\$nil	\$nil
Current Liabilities	\$6,679,109	\$7,537,997
Non-current Liabilities	\$27,174	\$49,115
Shareholders' equity	\$(6,486,380)	\$(7,362,149)
Revenue	\$nil	\$nil
Net Income	\$(1,512,918)	\$(3,621,884)
Net Cash Flow from Operations	\$(625,455)	\$(2,021,752)

SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in the Schedules. If the required details are included in Schedule A or B, provide specific reference to the page or note.

1. Related party transactions

All related party transactions have been disclosed in the Issuer's notes to the audited consolidated financial statements for the year ended January 31, 2026 (Note 14).

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.

- (c) The recorded amount of the transactions classified by financial statement category.
- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

2. Summary of securities issued and options granted during the period.

Summary of securities issued and options granted have been disclosed in the Issuer's notes to the audited consolidated financial statements for the year ended January 31, 2026 (Note 5 – Convertible Debentures, Note 8 – Common Shares, Note 9 – Share Purchase Warrants, Note 10 – Compensation Options and Note 11 – Long-term Incentive Plans).

Provide the following information for the Listed Issuer's fiscal year:

- (a) summary of securities issued during the period,

Date of Issue	Type of Security (common shares, convertible debentures, etc.)	Type of Issue (private placement, public offering, exercise of warrants, etc.)	Number	Price	Total Proceeds	Type of Consideration (cash, property, etc.)	Describe relationship of Person with Issuer (indicate if Related Person)	Commission Paid

- (b) summary of options granted during the period,

Date	Number	Name of Optionee if Related Person and relationship	Generic description of other Optionees	Exercise Price	Expiry Date	Market Price on date of Grant

3. Summary of securities as at the end of the reporting period.

Summary of securities has been provided in the Issuer's audited consolidated financial statements and notes to the consolidated financial statements for the year ended January 31, 2026 as indicated below.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of securities outstanding for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,

Consolidated statements of changes in shareholders' deficit

- (b) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and

Note 5 – Convertible Debentures

Note 8 – Common Shares

Note 9 – Share Purchase Warrants

Note 10 – Compensation Options

Note 11 – Long-term Incentive Plans

- (c) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

This section is not applicable.

4. List the names of the directors and officers and include the position(s) held and the date of appointment, as at the date this report is signed and filed.

Name of Director/Officer	Position(s) Held
<i>Doug Drysdale</i>	<i>Director and Chairman</i>
<i>Ahmad Doroudian</i>	<i>Director and Chief Executive Officer</i>
<i>Hooshmand Sheshbaradaran</i>	<i>Chief Operating Officer</i>
<i>Maira Ong</i>	<i>Chief Financial Officer and Corporate Secretary</i>
<i>Steven Sangha</i>	<i>Director</i>
<i>Ralph Anthony Pullen</i>	<i>Director</i>

5. Financial Resources

- a) State the business objectives that the Issuer expects to accomplish in

the forthcoming 12-month period;

The Issuer plans to complete all the necessary preclinical and investigational new drug ("IND") enabling toxicology studies, and related research and development for BETR-001, the Issuer's proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD").

- b) Describe each significant event or milestone that must occur for the business objectives in (a) to be accomplished and state the specific time period in which each event is expected to occur and the costs related to each event;

The Issuer must (A) secure funds to initiate and complete preclinical IND-enabling studies (approximately \$1.03 million) (June through November 2026), (B) secure funds of approximately \$700,000 for GMP manufacturing of drug supply (June 2026 through January 2027), (C) secure funds of approximately \$730,000 for IND clinical protocol, regulatory, patents and other (June 2026 through February 2027), and (D) secure further \$1.3 million for working capital (June 2026 through April 2027).

- c) Disclose the total funds available to the Issuer and the following breakdown of those funds:

- (i) the estimated consolidated working capital (deficiency) as of the most recent month end prior to filing the Listing Statement, and

The estimated working capital deficiency as of the most recent month end prior to filing of the Listing Statement is approximately \$6.7 million.

- (ii) the total other funds, and the sources of such funds, available to be used to achieve the objectives and milestones set out in paragraphs (a) and (b); and

The Issuer expects to secure \$2 million in equity or convertible debentures June 2026 and a further \$1.8 million in equity August/September 2026.

- (iii) describe in reasonable detail and, if appropriate, using tabular form, each of the principal purposes, with approximate amounts, for which the funds available described under the preceding paragraph will be used by the Issuer.

The Issuer expects to utilize approximately \$3.8 million (noted above) as follows:

<i>Preclinical IND-enabling studies</i>	<i>\$1,030,000</i>
<i>GMP manufacturing of drug supply</i>	<i>\$700,000</i>
<i>IND clinical protocol</i>	<i>\$208,000</i>
<i>Regulatory</i>	<i>\$95,000</i>
<i>Patents</i>	<i>\$195,000</i>
<i>Research consultants</i>	<i>\$240,000</i>
<i>Working capital</i>	<i>\$1,332,000</i>
<i>TOTAL</i>	<i>\$3,800,000</i>

6. Status of Operations

During the fiscal year, did the Listed Issuer

- (a) reduce or impair its principal operating assets; or

No.

- (b) cease or substantively reduce its business operations with respect to its stated business objectives in the most recent Listing Statement?

No.

7. Business Activity

- a) Activity for a mining or oil and gas Listed Issuer

- (i) For the most recent fiscal year, did the Listed Issuer have positive cash flow, significant revenue from operations, or \$50,000 in exploration or development expenditures?

Provide details. *This section is not applicable.*

- (ii) If the response to (i) above is “no”, for the three most recent fiscal years did the Listed Issuer have an aggregate of \$100,000 in exploration or development expenditures?

Provide details. *This section is not applicable.*

- b) Activity for industry segments other than mining or oil & gas

- (i) For the most recent fiscal year, did the Listed Issuer have positive cash flow, or \$100,000 in revenue from operations or \$100,000 in development expenditures?

Provide details. *No.*

- (ii) If the response to (i) above is “no”, for the three most recent fiscal years, did the Listed Issuer have either \$200,000 in operating revenues or \$200,000 in expenditures directly related to the development of the business?

Provide details. Yes. *For the years ended January 31, 2026, 2025 and 2024, the Issuer had research and development expenditures directly related to the development of its business of \$1,080,956.*

SCHEDULE A: AUDITED ANNUAL FINANCIAL STATEMENTS

SCHEDULE B: MANAGEMENT DISCUSSION AND ANALYSIS

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Annual Listing Summary.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated May 29, 2026.

Moira Ong
Name of Director or Senior Officer

"Moira Ong"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer BetterLife Pharma Inc.		For Year Ended January 31, 2026	Date of Report YY/MM/D 26/05/29
Issuer Address 1275 West 6 th Avenue, #300			
City/Province/Postal Code Vancouver/BC/V6H 1A6	Issuer Fax No. N/A	Issuer Telephone No. N/A	
Contact Name Moira Ong	Contact Position CFO	Contact Telephone No. (604) 551-5178	
Contact Email Address moira.ong@blifepharma.com	Web Site Address www.abetterlifepharma.com		